A Phase 1/2 interventional study of Pimasertib and Gemcitabine in Pancreatic Adenocarcinoma, sponsored by EMD Serono. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-13.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The research trial is testing the experimental treatment MSC1936369B in combination with Gemcitabine, in subjects with metastatic pancreatic adenocarcinoma. The study will be run in two parts:
Safety Run-In: Will determine the Maximum Tolerated Dose (MTD) and the recommended Phase II dose of MSC1936369B, when combined with gemcitabine, in subjects with metastatic pancreatic adenocarcinoma.
Phase II: Will assess the anti-tumor activity of MSC1936369B combined with gemcitabine compared to gemcitabine alone as first line treatment in subjects with metastatic pancreatic adenocarcinoma.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 141 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive pimasertib capsule orally once daily (qd) doses of 15, 30, 45, 68, 90, and 120 milligram (mg) on Day 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15,16, 17, 18, 19, 22, 23, 24, 25, 26 and gemcitabine 1000 milligram per square meter (mg/m\^2) intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks).
Drug: Pimasertib · Drug: Gemcitabine
Subjects will receive pimasertib capsule orally twice daily (bid) doses of 60 and 75 mg continuously for a 28-day cycle and gemcitabine 1000 mg/m\^2 intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks) (bid - continuous regimen).
Drug: Pimasertib · Drug: Gemcitabine
Subjects will receive gemcitabine 1000 mg/m\^2 IV infusion on for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and placebo matched to pimasertib orally bid - continuous regimen.
Drug: Gemcitabine · Drug: Placebo
Subjects will receive gemcitabine 1000 mg/m\^2 IV infusion for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and pimasertib capsule orally bid - continuous regimen.
Drug: Pimasertib · Drug: Gemcitabine
Also known as: MSC1936369B (MEK Inhibitor)
Safety Run-In Part: Number of Subjects With Dose Limiting Toxicities (DLTs)
DLT using the National Cancer Institute Common Terminology Criteria for Adverse Events(CTCAE) v3.0,was defined as any of the following toxicities at any dose level and judged to be possibly or probably related to trial medication by the Investigator and/or the Sponsor and relevant for the combination treatment: Grade 3/more non-hematological toxicity excluding: Subjects with liver involvement: Grade 4 asymptomatic increases in liver function tests and subject without liver involvement: Grade 3 asymptomatic increases in liver function tests reversible within 7 days. Grade 3 vomiting encountered despite adequate therapy. Grade 3 diarrhea encountered despite adequate anti diarrhea therapy. Grade 4 neutropenia greater (\>) 5 days duration or febrile neutropenia lasting for more than 1 day. Grade 4 thrombocytopenia \> 1 day/Grade 3 with bleeding. Grade 4 anemia: Any treatment delay \> 2 weeks due to drug-related adverse effects.
Time frame: Up to 28 days in Cycle 1
Phase II: Progression-Free Survival (PFS) Time
PFS was defined as the time from randomization to the first documentation of objective tumor progression (Complete Response (CR): Disappearance of all target lesions, Partial Response (PR): At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline, Progressive Disease (PD): At least 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started, or the appearance of 1 or more new lesions and stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started) or to death due to any cause, whichever occurred first. PFS calculated as (Months) = Date of first PD or death or censoring date minus date of randomization plus 1) divided by 30.4375.
Time frame: From the time of randomization to every 8 weeks up to end of treatment (EOT) (6 years)
Safety Run-In Part: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Permanent Treatment Discontinuation
An adverse event (AE) was any untoward medical occurrence in a subjects who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. All AEs (serious and non-serious) except AEs recorded with an onset date prior to the first day of drug administration unless a worsening of the event was recorded after the first dosing date, in which case the event was counted as a TEAE. TEAEs include both SAEs and non-SAEs.
Time frame: From the first dose of study drug administration until EOT (6 years)
Safety Run-In Part: Maximum Concentration (Cmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU) for Regimen 1
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Time to Reach Maximum Concentration (Tmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Time to Reach Apparent Terminal Half-Life (t1/2) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1
Plasma decay half-life was the time measured for the plasma concentration to decrease by one half.
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Area Under Curve (AUC: 0 to Infinity) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1
AUC:0 to infinity was a measure of the serum concentration of the drug over time. It was used to characterize drug absorption.
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1 of Cycle 1 for MSC1936369B, 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1 for Gemcitabine
Safety Run-In Part: Apparent Oral Clearance (CL/f) of Pimasertib (MSC1936369B): Regimen 1
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) was influenced by the fraction of the dose absorbed.
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Total Clearance (CL) of Gemcitabine: Regimen 1
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Oral Volume of Distribution (V/f) of Pimasertib (MSC1936369B): Regimen 1
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Apparent Volume of Distribution (V) of Gemcitabine: Regimen 1
Apparent volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Levels of Pharmacodynamic (Pd) Markers (Phosphorylated- Extracellular Signal-Regulated Kinase (ERK) in Peripheral Blood Mononuclear Cells [PBMCs]): Regimen 1
ERK phosphoprotein in peripheral blood monocytes (PBMCs) was analyzed from blood samples of all subjects in the SAF analysis set (safety-run part) only.
Time frame: pre-dose on Day 1, 2, 22 of Cycle 1; post-dose on Day 1, 22 of Cycle 1
Safety Run-In Part: Maximum Concentration (Cmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Area Under Curve (AUC:0 to Infinity) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU) Regimen 2
AUC:0 to infinity is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1 of Cycle 1 for MSC1936369B, 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1 for Gemcitabine
Safety Run-In Part: Time to Reach Maximum Concentration (Tmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Time to Reach Apparent Terminal Half-Life (t1/2) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Apparent Oral Clearance (CL/f) of Pimasertib (MSC1936369B): Regimen 2
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Total Clearance (CL) of Gemcitabine: Regimen 2
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Apparent Volume of Distribution (V) of Gemcitabine: Regimen 2
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Oral Volume of Distribution (V/f) of Pimasertib (MSC1936369B): Regimen 2
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Time frame: 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1
Safety Run-In Part: Levels of Pharmacodynamic (Pd) Markers (Phosphorylated- Extracellular Signal-Regulated Kinase (ERK) in Peripheral Blood Mononuclear Cells [PBMCs]): Regimen 2
ERK phosphoprotein in peripheral blood monocytes (PBMCs) was analyzed from blood samples of all subjects in the SAF analysis set (safety-run part) only.
Time frame: pre-dose on Day 1, 2, 22 of Cycle 1; post-dose on Day 1, 22 of Cycle 1
Phase II: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Permanent Treatment Discontinuation
An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. All AEs (serious and non-serious) except AEs recorded with an onset date prior to the first day of drug administration unless a worsening of the event was recorded after the first dosing date, in which case the event was counted as a TEAE. TEAEs include both SAEs and non-SAEs.
Time frame: From the first dose of study drug administration until EOT (6 years)
Phase II: Percentage of Subjects With Best Overall Response (BOR)
Best overall response was defined as the presence of at least one complete response (CR), partial response (PR) or Stable Disease (SD) (using RECIST v1.0) during treatment. CR: Disappearance of all target lesions, PR: At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline and SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started.
Time frame: Baseline, every 8 weeks up to end of treatment (EOT i.e. 6 years)
Phase II: Percentage of Subjects With Clinical Benefit
Clinical Benefit was defined as the presence of at least one CR, PR or Stable Disease (SD) (using RECIST v1.0) during treatment. CR: Disappearance of all target lesions, PR: At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline and SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started.
Time frame: Baseline, every 8 weeks up to end of treatment (EOT i.e. 6 years)
Phase II: Time to Progression (TTP)
Time to progression (TTP) is defined as the time (in months) from the randomization date to the date of progression prior to the start of any subsequent therapy for the primary disease, as reported and documented by the Investigator (i.e. radiological progression per RECIST).
Time frame: From randomization every 8 weeks up to EOT (6 years)
Phase II: Overall Survival (OS) Time
Overall survival (OS) time is defined as the time (in months) from randomization to death.
Time frame: Baseline, every 8 weeks up to EOT (6 years)
Phase II: Absorption Rate Constant (ka) of Pimasertib (MSC1936369B)
Time frame: Baseline, every 8 weeks up to EOT (6 years)
Phase II: Clearance From Central Compartment (CL/f) and Intercompartmental Clearance (Q/f) of Pimasertib (MSC1936369B)
Time frame: Baseline, every 8 weeks up to EOT (6 years)
Phase II: Volume of Central Compartment (V1/f) and Volume of Peripheral Compartment (V2/f) of Pimasertib (MSC1936369B)
Time frame: Baseline, every 8 weeks up to EOT (6 years)
First/last subject (informed consent): Nov 2009/Jul 2013. Clinical data cut off: Dec 2013, Study completion date: April 2015
| Milestone | Safety Run-in Part: Regimen 1 | Safety Run-in Part: Regimen 2 | Phase II: Arm 1 (Gemcitabine + Placebo) | Phase II: Arm 2 (Gemcitabine + Pimasertib) |
|---|---|---|---|---|
| Started | 27 | 26 | 0 | 0 |
| Completed | 27 | 26 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Safety Run-in Part: Regimen 1 | Safety Run-in Part: Regimen 2 | Phase II: Arm 1 (Gemcitabine + Placebo) | Phase II: Arm 2 (Gemcitabine + Pimasertib) |
|---|---|---|---|---|
| Started | 0 | 0 | 44 | 44 |
| Treated (safety analysis set [saf]) | 0 | 0 | 42 | 45 |
| Completed | 0 | 0 | 44 | 44 |
| Not completed | 0 | 0 | 0 | 0 |
DLT using the National Cancer Institute Common Terminology Criteria for Adverse Events(CTCAE) v3.0,was defined as any of the following toxicities at any dose level and judged to be possibly or probably related to trial medication by the Investigator and/or the Sponsor and relevant for the combination treatment: Grade 3/more non-hematological toxicity excluding: Subjects with liver involvement: Grade 4 asymptomatic increases in liver function tests and subject without liver involvement: Grade 3 asymptomatic increases in liver function tests reversible within 7 days. Grade 3 vomiting encountered despite adequate therapy. Grade 3 diarrhea encountered despite adequate anti diarrhea therapy. Grade 4 neutropenia greater (\>) 5 days duration or febrile neutropenia lasting for more than 1 day. Grade 4 thrombocytopenia \> 1 day/Grade 3 with bleeding. Grade 4 anemia: Any treatment delay \> 2 weeks due to drug-related adverse effects.
| subjects | Safety Run-in Part Regimen 1: 15 mg | Safety Run-in Part Regimen 1: 30 mg | Safety Run-in Part Regimen 1: 45 mg | Safety Run-in Part Regimen 1: 68 mg | Safety Run-in Part Regimen 1: 90 mg | Safety Run-in Part Regimen 1: 120 mg | Safety Run-in Part Regimen 2: 60 mg | Safety Run-in Part Regimen 2: 75 mg |
|---|---|---|---|---|---|---|---|---|
| Safety Run-In Part: Number of Subjects With Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
PFS was defined as the time from randomization to the first documentation of objective tumor progression (Complete Response (CR): Disappearance of all target lesions, Partial Response (PR): At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline, Progressive Disease (PD): At least 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started, or the appearance of 1 or more new lesions and stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started) or to death due to any cause, whichever occurred first. PFS calculated as (Months) = Date of first PD or death or censoring date minus date of randomization plus 1) divided by 30.4375.
| months | Phase II: Arm 1 | Phase II: Arm 2 |
|---|---|---|
| Phase II: Progression-Free Survival (PFS) Time | 2.83 (1.77 to 3.88) | 3.75 (2.63 to 5.09) |
An adverse event (AE) was any untoward medical occurrence in a subjects who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. All AEs (serious and non-serious) except AEs recorded with an onset date prior to the first day of drug administration unless a worsening of the event was recorded after the first dosing date, in which case the event was counted as a TEAE. TEAEs include both SAEs and non-SAEs.
| subjects | Safety Run-in Part: Regimen 1 | Safety Run-in Part: Regimen 2 |
|---|---|---|
| TEAEs | 27 | 26 |
| Serious TEAEs | 18 | 20 |
| Permanent treatment discontinuation of pimasertib | 12 | 16 |
| Permanent treatment discontinuation of gemcitabine | 14 | 15 |
| nanogram per milliliter (ng/mL) | Regimen 1: 15 mg | Regimen 1: 30 mg | Regimen 1: 45 mg | Regimen 1: 68 mg | Regimen 1: 90 mg | Regimen 1: 120 mg |
|---|---|---|---|---|---|---|
| MSC1936369B on Days 1 (n=4,3,3,3,3,11) | 32.3 ± 107.5 | 131.0 ± 32.9 | 205.8 ± 30.0 | 151.3 ± 40.1 | 485.3 ± 58.7 | 484.3 ± 39.8 |
| MSC1936369B on Days 22 (n= 3,3,3,2,3,10) | 29.6 ± 39.8 | 174.2 ± 29.6 | 261.8 ± 52.0 | 212.5 ± 16.9 | 409.1 ± 44.1 | 252.9 ± 477.0 |
| Gemcitabine (dFdC) on Day 1 (n=4,3,3,3,3,11) | 69540.5 ± 1729.4 | 21207.3 ± 21.0 | 17759.9 ± 34.1 | 29762.1 ± 76.7 | 15606.3 ± 23.1 | 23880.7 ± 83.8 |
| Gemcitabine (dFdC) on Day 22 (n= 2,3,3,2,3,9) | 24115.8 ± 71.9 | 11799.7 ± 167.7 | 181.9 ± 39158542.7 | 163196.2 ± 3183.3 | 669.5 ± 3278825923 | 23207.2 ± 99.5 |
| Metabolite (dFdU) on Day 1 (n= 4,3,3,3,3,11) | 29359.8 ± 8.5 | 33171.6 ± 21.2 | 34868.9 ± 12.8 | 33804.4 ± 16.7 | 37786.4 ± 13.6 | 34038.7 ± 29.7 |
| Metabolite (dFdU) on Day 22 (n= 2,3,3,2,3,10) | 29677.6 ± 3.0 | 38265.2 ± 54.3 | 10569.2 ± 449.2 | 32869.2 ± 8.7 | 17135.0 ± 227.5 | 21077.5 ± 179.5 |
| hours | Regimen 1: 15 mg | Regimen 1: 30 mg | Regimen 1: 45 mg | Regimen 1: 68 mg | Regimen 1: 90 mg | Regimen 1: 120 mg |
|---|---|---|---|---|---|---|
| Tmax: MSC1936369B on Day 1 (n= 4,3,3,3,3,11) | 1.250 (1.00 to 1.50) | 1.000 (1.00 to 2.50) | 1.533 (1.00 to 2.00) | 2.000 (0.67 to 8.00) | 1.083 (1.00 to 2.00) | 1.500 (0.50 to 4.00) |
| Tmax: MSC1936369B on Day 22 (n= 3,3,3 2,3,10) | 2.017 (1.28 to 4.00) | 1.000 (0.50 to 2.50) | 1.000 (0.50 to 1.58) | 1.750 (1.00 to 2.50) | 1.500 (1.00 to 1.75) | 2.000 (0.83 to 8.00) |
| Tmax: Gemcitabine (dFdC) on Day 1 (n=4,3,3,3,3,11) | 0.38 (0.25 to 0.50) | 0.50 (0.25 to 0.50) | 0.25 (0.25 to 0.50) | 0.25 (0.25 to 1.17) | 0.25 (0.25 to 0.38) | 0.27 (0.25 to 0.75) |
| Tmax: Gemcitabine (dFdC) on Day 22 (n=2,3,3,2,3,9) | 0.42 (0.33 to 0.50) | 0.50 (0.50 to 1.58) | 0.53 (0.25 to 2.00) | 1.04 (1.00 to 1.08) | 0.25 (0.23 to 24.00) | 0.50 (0.25 to 0.75) |
| Tmax: Metabolite (dFdU) on Day 1 (n=4,3,3,3,3,11) | 0.64 (0.50 to 1.00) | 0.50 (0.50 to 0.75) | 0.50 (0.50 to 0.77) | 0.75 (0.67 to 1.00) | 0.50 (0.38 to 0.50) | 0.50 (0.25 to 0.75) |
| Tmax: Metabolite (dFdU) on Day 22 (n=2,3,3,2,3,10 | 0.54 (0.33 to 0.75) | 0.75 (0.50 to 1.58) | 1.00 (0.73 to 2.00) | 0.67 (0.33 to 1.00) | 0.75 (0.50 to 24.00) | 0.75 (0.00 to 1.00) |
Plasma decay half-life was the time measured for the plasma concentration to decrease by one half.
| hours | Regimen 1: 15 mg | Regimen 1: 30 mg | Regimen 1: 45 mg | Regimen 1: 68 mg | Regimen 1: 90 mg | Regimen 1: 120 mg |
|---|---|---|---|---|---|---|
| t1/2: MSC1936369B on Day 1 (n=4,3,3,2,3,11) | 4.008 (2.539 to 6.131) | 3.807 (3.373 to 6.648) | 3.833 (3.612 to 6.477) | 4.232 (3.382 to 5.083) | 5.036 (4.361 to 5.120) | 4.580 (3.394 to 6.938) |
| t1/2: MSC1936369B on Day 22 (n=2,2,3,2,3,8) | 8.660 (4.709 to 12.61) | 6.100 (4.878 to 7.322) | 3.254 (3.048 to 6.999) | 5.744 (3.829 to 7.658) | 3.162 (2.903 to 6.341) | 4.825 (2.829 to 8.642) |
| t1/2: Gemcitabine (dFdC) on Day 1 (n=4,3,3,3,3,11) | 4.274 (2.100 to 7.519) | 2.461 (1.239 to 6.821) | 2.421 (0.7070 to 5.709) | 5.327 (5.148 to 5.338) | 8.940 (5.565 to 9.982) | 6.242 (0.8913 to 11.90) |
| t1/2: Gemcitabine (dFdC) on Day 22 (n=2,2,1,2,2,9) | 7.449 (6.032 to 8.866) | 4.553 (2.403 to 6.702) | 0.9152 (0.9152 to 0.9152) | 4.493 (2.721 to 6.266) | 8.213 (6.665 to 9.762) | 4.680 (0.8685 to 8.490) |
| t1/2: Metabolite (dFdU) on Day 1 (n=4,3,3,3,3,11) | 8.956 (8.129 to 14.68) | 10.49 (4.336 to 10.70) | 9.836 (9.383 to 14.69) | 11.52 (9.344 to 12.36) | 8.349 (7.191 to 9.551) | 10.93 (8.802 to 15.48) |
| t1/2: Metabolite (dFdU) on Day 22(n=2,2,2,2,2,10) | 7.731 (6.978 to 8.483) | 8.925 (8.299 to 9.552) | 8.843 (5.427 to 12.26) | 11.14 (9.119 to 13.17) | 10.21 (6.782 to 13.64) | 12.17 (3.468 to 211.2) |
AUC:0 to infinity was a measure of the serum concentration of the drug over time. It was used to characterize drug absorption.
| hour*nanogram per milliliter (h*ng/mL) | Regimen 1:15 mg | Regimen 1: 30 mg | Regimen 1: 45 mg | Regimen 1: 68 mg | Regimen 1: 90 mg | Regimen1: 120 mg |
|---|---|---|---|---|---|---|
| AUC: MSC1936369B on Day 1 (n=4,3,3,3,3,11) | 162.8 ± 25.3 | 516.3 ± 32.9 | 881.1 ± 37.1 | 774.8 ± 58.9 | 1729.9 ± 32.3 | 2175.1 ± 53.0 |
| AUC: Gemcitabine (dFdC) on Day 1(n=4,3,3,3,3,11) | 29536.1 ± 473.4 | 13536.5 ± 40.4 | 10053.3 ± 24.6 | 18956.0 ± 37.2 | 8178.4 ± 28.7 | 11680.1 ± 59.0 |
| AUC: Gemcitabine (dFdC) on Day 22(n=2,2,1,2,2,9) | 10828.0 ± 93.8 | 12019.6 ± 29.5 | 9093.2 ± NA | 76448.7 ± 466.6 | 9604.8 ± 11.9 | 10598.0 ± 66.7 |
| AUC: Metabolite (dFdU) on Day 1 (n=4,3,3,3,3,11) | 245795.5 ± 10.8 | 228032.9 ± 27.6 | 276968.3 ± 28.9 | 259816.2 ± 9.2 | 239902.9 ± 27.1 | 240293.8 ± 15.0 |
| AUC: Metabolite (dFdU) on Day 22 (n=2,2,2,2,2,10) | 190952.6 ± 9.3 | 376280.5 ± 13.0 | 217930.8 ± 70.4 | 327424.8 ± 2.0 | 248496.4 ± 5.2 | 247430.7 ± 29.2 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) was influenced by the fraction of the dose absorbed.
| Liter per hour (L/h) | Regimen 1:15 mg | Regimen 1: 30 mg | Regimen 1: 45 mg | Regimen 1: 68 mg | Regimen 1: 90 mg | Regimen 1: 120 mg |
|---|---|---|---|---|---|---|
| CL/f: MSC1936369B on Day 1 (n=4,3,3,2,3,11) | 92.152 ± 25.3 | 58.104 ± 32.9 | 51.072 ± 37.1 | 87.765 ± 58.9 | 52.025 ± 32.3 | 55.171 ± 53.0 |
| CL/f: MSC1936369B on Day 22 (n=2,2,3,2,3,9) | 74.143 ± 43.6 | 42.484 ± 31.2 | 44.579 ± 23.1 | 56.502 ± 7.5 | 50.873 ± 59.6 | 55.723 ± 57.8 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
| liter/hour | Regimen 1: 15 mg | Regimen 1: 30 mg | Regimen 1: 45 mg | Regimen 1: 68 mg | Regimen 1: 90 mg | Regimen 1: 120 mg |
|---|---|---|---|---|---|---|
| CL: Gemcitabine on Day 1 (n=4,3,3,3,3,11) | 60.537 ± 483.4 | 133.88 ± 45.1 | 190.52 ± 26.0 | 95.96 ± 47.7 | 210.25 ± 27.9 | 151.93 ± 54.7 |
| CL: Gemcitabine on Day 22 (n=2,2,1,2,2,9) | 163.37 ± 93.7 | 156.93 ± 20.1 | 190.69 ± NA | 25.123 ± 431.2 | 183.97 ± 11.6 | 164.6 ± 71.7 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
| liter | Regimen 1: 15 mg | Regimen 1: 30 mg | Regimen 1: 45 mg | Regimen 1: 68 mg | Regimen 1: 90 mg | Regimen 1: 120 mg |
|---|---|---|---|---|---|---|
| V/f: MSC1936369B on Day 1 (n=4,3,3,2,3,11) | 528.62 ± 63.1 | 369.12 ± 5.0 | 329.80 ± 28.4 | 524.96 ± 26.2 | 362.29 ± 34.0 | 367.25 ± 50.5 |
| V/f: MSC1936369B on Day 22 (n=2,2,3,2,3,8) | 824.33 ± 156.8 | 366.30 ± 1.8 | 264.31 ± 43.8 | 441.40 ± 43.4 | 284.42 ± 35.1 | 414.38 ± 66.8 |
Apparent volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
| liter | Regimen 1: 15 mg | Regimen 1: 30 mg | Regimen 1: 45 mg | Regimen 1: 68 mg | Regimen 1: 90 mg | Regimen 1: 120 mg |
|---|---|---|---|---|---|---|
| V: Gemcitabine (dFdC) on Day 1 (n= 4,3,3,3,3,11) | 359.55 ± 635.6 | 531.23 ± 64.7 | 587.64 ± 206.3 | 729.65 ± 46.3 | 2402.1 ± 59.5 | 1270.1 ± 82.0 |
| V: Gemcitabine (dFdC) on Day 22 (n=2,2,1,2,2,9) | 1723.6 ± 55.9 | 908.50 ± 56.5 | 251.79 ± NA | 149.65 ± 1453.7 | 2140.8 ± 15.5 | 805.15 ± 138.0 |
ERK phosphoprotein in peripheral blood monocytes (PBMCs) was analyzed from blood samples of all subjects in the SAF analysis set (safety-run part) only.
| Fluorescence Intensity | Regimen 1:15 mg | Regimen 1: 30 mg | Regimen 1: 45 mg | Regimen 1: 68 mg | Regimen 1: 90 mg | Regimen1: 120 mg |
|---|---|---|---|---|---|---|
| Cycle 1 Day 1 Pre-dose (n=3,2,2,3,3,7) | 5.389 ± 0.797 | 6.476 ± 0.997 | 4.767 ± 0.114 | 6.509 ± 2.240 | 4.608 ± 0.197 | 4.229 ± 1.719 |
| Cycle 1 Day 1 Post-dose (n=3,2,2,3,2,6) | 1.611 ± 0.537 | 2.061 ± 0.825 | 0.837 ± 0.149 | 3.881 ± 5.387 | 1.059 ± 0.042 | 0.946 ± 0.248 |
| Cycle 1 Day 2 Pre-dose (n=3,2,1,2,2,6) | 4.818 ± 0.808 | 6.719 ± 2.835 | 3.902 ± NA | 2.768 ± 0.330 | 4.874 ± 2.119 | 3.636 ± 1.755 |
| Cycle 1 Day 22 Pre-dose (n=2,1,2,1,3,5) | 5.242 ± 0.210 | 6.000 ± NA | 1.978 ± 2.539 | 8.653 ± NA | 4.252 ± 1.259 | 3.453 ± 0.860 |
| Cycle 1 Day 22 Post-dose (n=0,0,0,0,2) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 4.130 ± 1.772 |
| nanogram per milliliter (ng/mL) | Regimen 2: 60 mg | Regimen 2: 75 mg |
|---|---|---|
| MSC1936369B on Day 1 (n= 12,13) | 175.7 ± 65.0 | 345.5 ± 52.8 |
| MSC1936369B on Day 22 (n=10,9) | 228.2 ± 59.0 | 244.8 ± 31.9 |
| Gemcitabine (dFdC) on Day 1 (n=11,14) | 27849.2 ± 344.0 | 17663.9 ± 173.3 |
| Gemcitabine (dFdC) on Day 22 (n=9,4) | 21589.7 ± 118.8 | 18733.4 ± 88.6 |
| Gemcitabine Metabolite (dFdU) on Day 1 (n=11, 10) | 33033.3 ± 11.8 | 31623.9 ± 25.4 |
| Gemcitabine Metabolite (dFdU) on Day 22 (n=10,5) | 13455.5 ± 546.0 | 18298.7 ± 247.7 |
AUC:0 to infinity is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.
| hour*nanogram per milliliter (h*ng/mL) | Regimen 2: 60 mg | Regimen 1: 75 mg |
|---|---|---|
| AUC: MSC1936369B on Day 1 (n= 10, 11) | 704.3 ± 69.4 | 1427.0 ± 30.0 |
| AUC: Gemcitabine (dFdC) on Day 1 (n= 11, 14) | 11932.0 ± 343.0 | 8065.5 ± 176.2 |
| AUC: Gemcitabine (dFdC) on Day 22 (n= 9, 4) | 10719.1 ± 84.9 | 10102.3 ± 72.0 |
| AUC: Metabolite (dFdU) on Day 1 (n= 11, 13) | 189007.0 ± 40.6 | 234934.8 ± 29.9 |
| AUC: Metabolite (dFdU) on Day 22 (n= 10, 5) | 177504.5 ± 171.5 | 256714.9 ± 37.3 |
| hours | Regimen 2: 60 mg | Regimen 2: 75 mg |
|---|---|---|
| Tmax: MSC1936369B on Day 1 (n=12,13) | 2.000 (0.50 to 3.98) | 1.583 (0.50 to 7.98) |
| Tmax: MSC1936369B on Day 22 (n=10,9) | 1.500 (0.25 to 4.40) | 2.000 (0.58 to 4.00) |
| Tmax: Gemcitabine (dFdC) on Day 1 (n=11,14) | 0.50 (0.25 to 0.73) | 0.38 (0.25 to 0.75) |
| Tmax: Gemcitabine (dFdC) on Day 22 (n=9,4) | 0.25 (0.00 to 0.50) | 0.25 (0.25 to 0.50) |
| Tmax: Metabolite (dFdU) on Day 1 (n=11,13) | 0.67 (0.50 to 0.75) | 0.67 (0.25 to 1.00) |
| Tmax: Metabolite (dFdU) on Day 22 (n=10,5) | 0.50 (0.00 to 2.00) | 0.50 (0.50 to 0.75) |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hours | Regimen 2: 60 mg | Regimen 2: 75 mg |
|---|---|---|
| t1/2: MSC1936369B on Day 1 (n=10,11) | 2.757 (2.183 to 3.557) | 2.603 (1.775 to 4.910) |
| t1/2: MSC1936369B on Day 22 (n=8,5) | 3.425 (2.584 to 10.60) | 3.188 (2.296 to 4.617) |
| t1/2: Gemcitabine (dFdC) on Day 1 (n=11,14) | 5.258 (0.796 to 8.757) | 5.376 (0.6681 to 11.64) |
| t1/2: Gemcitabine (dFdC) on Day 22 (n=9,4) | 5.522 (3.759 to 11.45) | 5.249 (0.3198 to 9.505) |
| t1/2: Metabolite (dFdU) on Day 1 (n=11,13) | 9.471 (6.559 to 13.10) | 10.26 (7.123 to 12.92) |
| t1/2: Metabolite (dFdU) on Day 22 (n=10,5) | 10.68 (6.543 to 441.9) | 13.58 (7.575 to 17.535) |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
| Liter per hour (L/H) | Regimen 2: 60 mg | Regimen 2: 75 mg |
|---|---|---|
| CL/f: MSC1936369B on Day 1 (n=10,11) | 85.186 ± 69.4 | 52.558 ± 30.0 |
| CL/f: MSC1936369B on Day 22 (n=8,5) | 70.163 ± 63.2 | 68.312 ± 24.9 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
| liter/hour | Regimen 2: 60 mg | Regimen 2: 75 mg |
|---|---|---|
| CL: Gemcitabine on Day 1 (n=11, 14) | 145.65 ± 363.2 | 221.46 ± 186.0 |
| CL: Gemcitabine on Day 22 (n=9, 4) | 164.68 ± 81.4 | 183.85 ± 73.5 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
| liter | Regimen 2: 60 mg | Regimen 2: 75 mg |
|---|---|---|
| V: Gemcitabine on Day 1 (n=11,14) | 716.12 ± 343.3 | 1059.0 ± 196.6 |
| V: Gemcitabine on Day 22 (n=9,4) | 1590.8 ± 120.5 | 801.90 ± 130.3 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
| liter | Regimen 2: 60 mg | Regimen 2: 75 mg |
|---|---|---|
| V/f: MSC1936369B on Day 1 (n= 10,11) | 335.56 ± 66.3 | 213.24 ± 37.7 |
| V/f: MSC1936369B on Day 22 (n=8,5) | 389.56 ± 47.1 | 319.02 ± 35.5 |
ERK phosphoprotein in peripheral blood monocytes (PBMCs) was analyzed from blood samples of all subjects in the SAF analysis set (safety-run part) only.
| Fluorescence Intensity | Regimen 2: 60 mg | Regimen 2: 75 mg |
|---|---|---|
| Cycle 1 Day 1 Pre-dose (n=7,4) | 6.081 ± 0.827 | 5.874 ± 2.239 |
| Cycle 1 Day 1 Post-dose (n=5,3) | 1.520 ± 0.109 | 1.048 ± 0.155 |
| Cycle 1 Day 2 Pre-dose (n=7,3) | 3.877 ± 2.099 | 2.263 ± 0.593 |
| Cycle 1 Day 22 Pre-dose (n=6,2) | 2.728 ± 0.818 | 2.295 ± 0.510 |
| Cycle 1 Day 22 Post-dose (n=3,1) | 1.443 ± 0.458 | 1.111 ± NA |
An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. All AEs (serious and non-serious) except AEs recorded with an onset date prior to the first day of drug administration unless a worsening of the event was recorded after the first dosing date, in which case the event was counted as a TEAE. TEAEs include both SAEs and non-SAEs.
| subjects | Phase II: Arm 1 | Phase II: Arm 2 |
|---|---|---|
| TEAEs | 40 | 45 |
| Serious TEAEs | 28 | 35 |
| TEAEs Leading to Treatment Discontinuation | 10 | 21 |
Best overall response was defined as the presence of at least one complete response (CR), partial response (PR) or Stable Disease (SD) (using RECIST v1.0) during treatment. CR: Disappearance of all target lesions, PR: At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline and SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started.
| percentage of subjects | Phase II: Arm 1 | Phase II: Arm 2 |
|---|---|---|
| CR | 0 | 0 |
| PR | 9.1 | 9.1 |
| SD | 36.4 | 50.0 |
| PD | 29.5 | 20.5 |
| Missing | 25 | 20.5 |
Clinical Benefit was defined as the presence of at least one CR, PR or Stable Disease (SD) (using RECIST v1.0) during treatment. CR: Disappearance of all target lesions, PR: At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline and SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started.
| percentage of subjects | Phase II: Arm 1 | Phase II: Arm 2 |
|---|---|---|
| Phase II: Percentage of Subjects With Clinical Benefit | 45.5 | 59.1 |
Time to progression (TTP) is defined as the time (in months) from the randomization date to the date of progression prior to the start of any subsequent therapy for the primary disease, as reported and documented by the Investigator (i.e. radiological progression per RECIST).
| months | Phase II: Arm 1 | Phase II: Arm 2 |
|---|---|---|
| Phase II: Time to Progression (TTP) | 3.78 (1.87 to 5.55) | 5.09 (3.75 to 6.47) |
Overall survival (OS) time is defined as the time (in months) from randomization to death.
| months | Phase II: Arm 1 | Phase II: Arm 2 |
|---|---|---|
| Phase II: Overall Survival (OS) Time | 6.64 (5.06 to NA) | 9.33 (3.71 to NA) |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over From the first dose of study drug administration until EOT (6 years). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Run-in Part: Regimen 1 | — | 18/27 (66.7%) | 27/27 (100%) |
| Safety Run-in Part: Regimen 2 | — | 20/26 (76.9%) | 26/26 (100%) |
| Phase II: Arm 1 | — | 28/42 (66.7%) | 39/42 (92.9%) |
| Phase II: Arm 2 | — | 35/45 (77.8%) | 44/45 (97.8%) |
| Event | Safety Run-in Part: Regimen 1 | Safety Run-in Part: Regimen 2 | Phase II: Arm 1 | Phase II: Arm 2 |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 2/27 | 6/26 | 5/42 | 5/45 |
| Disease progressionGeneral disorders | 1/27 | 0/26 | 5/42 | 4/45 |
| CholangitisHepatobiliary disorders | 3/27 | 1/26 | 2/42 | 2/45 |
| OverdoseInjury, poisoning and procedural complications | 0/27 | 1/26 | 3/42 | 5/45 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/27 | 1/26 | 0/42 | 1/45 |
| VomitingGastrointestinal disorders | 0/27 | 1/26 | 4/42 | 4/45 |
| Blood bilirubin increasedInvestigations | 0/27 | 0/26 | 4/42 | 0/45 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/27 | 1/26 | 0/42 | 4/45 |
| Retinal Vein OcclusionEye disorders | 0/27 | 2/26 | 0/42 | 0/45 |
| Retinal detachmentEye disorders | 0/27 | 2/26 | 1/42 | 1/45 |
| Event | Safety Run-in Part: Regimen 1 | Safety Run-in Part: Regimen 2 | Phase II: Arm 1 | Phase II: Arm 2 |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 14/27 | 19/26 | 8/42 | 20/45 |
| ThrombocytopeniaBlood and lymphatic system disorders | 17/27 | 13/26 | 9/42 | 16/45 |
| NauseaGastrointestinal disorders | 16/27 | 15/26 | 15/42 | 23/45 |
| Oedema peripheralGeneral disorders | 14/27 | 15/26 | 8/42 | 22/45 |
| FatigueGeneral disorders | 15/27 | 5/26 | 17/42 | 17/45 |
| Retinal detachmentEye disorders | 10/27 | 14/26 | 1/42 | 10/45 |
| NeutropeniaBlood and lymphatic system disorders | 14/27 | 6/26 | 17/42 | 17/45 |
| PyrexiaGeneral disorders | 14/27 | 11/26 | 12/42 | 17/45 |
| AstheniaGeneral disorders | 8/27 | 13/26 | 6/42 | 9/45 |
| VomitingGastrointestinal disorders | 13/27 | 12/26 | 11/42 | 22/45 |
The safety analysis set (SAF) analysis set for the safety run-in part included subjects who received at least 1 (non-zero) administration of trial medication (pimasertib or gemcitabine). For Phase II: Intention-to-treat (ITT) set included subjects who were randomized, as per Interactive Voice Response System (IVRS).
| Age, Categorical(Participants) | Safety Run-in Part: Regimen 1 | Safety Run-in Part: Regimen 2 | Phase II: Arm 1 (Gemcitabine + Placebo) | Phase II: Arm 2 (Gemcitabine + Pimasertib) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 16 | 19 | 25 | 28 | 88 |
| >=65 years | 11 | 7 | 19 | 16 | 53 |
| Sex: Female, Male(Participants) | Safety Run-in Part: Regimen 1 | Safety Run-in Part: Regimen 2 | Phase II: Arm 1 (Gemcitabine + Placebo) | Phase II: Arm 2 (Gemcitabine + Pimasertib) | Total |
|---|---|---|---|---|---|
| Female | 9 | 8 | 22 | 17 | 56 |
| Male | 18 | 18 | 22 | 27 | 85 |
Ran from Nov 2009 to primary completion in Dec 2013, 49 months.
Results were first posted in Jun 2017, 3 years 5 months after primary completion.
Of 195 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 49 months is below that.
Counting every sponsor, half of 297 studies reached it within 60 months; a quarter within 39 and three quarters within 89.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pimasertib